Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock

This article originally appeared here.
Share this content:
Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock
Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock

WEDNESDAY, Aug. 3, 2016 (HealthDay News) -- Among adults with septic shock, early use of vasopressin does not improve the number of kidney failure-free days versus norepinephrine, according to a study published in the Aug. 2 issue of the Journal of the American Medical Association.

Anthony C. Gordon, M.D., from Imperial College London, and colleagues compared the effect of early vasopressin versus norepinephrine on kidney failure. Adult patients with septic shock requiring vasopressors were enrolled and randomized to vasopressin and hydrocortisone (101 patients), vasopressin and placebo (104 patients), norepinephrine and hydrocortisone (101 patients), or norepinephrine and placebo (103 patients).

The researchers found that 57.0 percent of survivors in the vasopressin group and 59.2 percent in the norepinephrine group never developed kidney failure (difference, −2.3 percent [95 percent confidence interval (CI), −13.0 to 8.5 percent]). For patients who did not survive, who experienced kidney failure, or both, the median number of kidney failure-free days was nine days in the vasopressin group and 13 days in the norepinephrine group (difference, −4 days [95 percent CI, −11 to 5]). The vasopressin group had less use of renal replacement therapy (25.4 versus 35.3 percent; difference, −9.9 percent [95 percent CI, −19.3 to −0.6 percent]). Just over 10 percent (10.7 percent) had a serious adverse event in the vasopressin group compared to 8.3 percent in the norepinephrine group (difference, 2.5 percent [95 percent CI, −3.3 to 8.2 percent]).

"Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin, and larger trials may be warranted to assess this further," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »